• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Tuesday

    5/31/22 12:06:15 PM ET
    $ALXO
    $BIG
    $BNR
    $CGA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Department/Specialty Retail Stores
    Consumer Discretionary
    Get the next $ALXO alert in real time by email

     

    On Tuesday, 36 companies achieved new lows for the year.

    Things to Consider About Today's 52-Week Lows:

    • The largest company in terms of market cap to set a new 52-week low was Clearwater Analytics Hldg (NYSE:CWAN).
    • The smallest company in terms of market cap to set a new 52-week low was Genocea Biosciences (NASDAQ:GNCA).
    • Outlook Therapeutics (NASDAQ:OTLK)'s stock fell the most, as it traded down 37.33% to reach a new 52-week low.
    • Burning Rock Biotech (NASDAQ:BNR)'s stock showed potential to rebound, rebounding up 0.69% after reaching a new 52-week low.

    On Tuesday, the following stocks set new 52-week lows:

    • Clearwater Analytics Hldg (NYSE:CWAN) stock broke to a new 52-week low of $14.41 on Tuesday. Shares of the company traded down 5.41%.
    • PTC Therapeutics (NASDAQ:PTCT) stock broke to a new 52-week low of $29.37 on Tuesday. Shares of the company traded down 2.14%.
    • Iovance Biotherapeutics (NASDAQ:IOVA) shares set a new 52-week low of $6.65. The stock traded down 4.13%.
    • Big Lots (NYSE:BIG) shares fell to $24.75 on Tuesday, setting a new 52-week low with a shift of down 7.91%.
    • Community Health Systems (NYSE:CYH) shares moved down 1.48% on Tuesday to hit a new 52-week low of $5.11, drifting down 1.48%.
    • SVF Inv Corp 3 (NASDAQ:SVFC) stock broke to a new 52-week low of $9.26 on Tuesday. Shares of the company traded down 5.31%.
    • LexinFintech Holdings (NASDAQ:LX) shares moved down 16.67% on Tuesday to hit a new 52-week low of $1.89, drifting down 16.67%.
    • Cepton (NASDAQ:CPTN) stock dropped to a yearly low on Tuesday of $2.33. Shares traded down 2.08%.
    • ALX Oncology Holdings (NASDAQ:ALXO) shares set a new 52-week low of $7.50. The stock traded down 5.47%.
    • Theseus Pharmaceuticals (NASDAQ:THRX) stock hit $6.53 on Tuesday morning, setting a new 52-week low for a change of down 1.0%.
    • Burning Rock Biotech (NASDAQ:BNR) stock achieved a new 52-week low on Tuesday morning, hitting $2.34 and moving up 0.69%.
    • Outlook Therapeutics (NASDAQ:OTLK) shares set a new 52-week low of $0.68. The stock traded down 37.33%.
    • Plumas (NASDAQ:PLBC) shares moved down 3.82% on Tuesday to hit a new 52-week low of $27.70, drifting down 3.82%.
    • Natuzzi (NYSE:NTZ) stock drifted down 7.03% on Tuesday morning to hit a new 52-week low of $9.20.
    • Cortexyme (NASDAQ:CRTX) shares hit a yearly low of $2.63. The stock was down 0.74% on the session.
    • Liberty TripAdvisor Hldgs (NASDAQ:LTRPA) shares hit a yearly low of $1.08. The stock was down 8.82% on the session.
    • China Green Agriculture (NYSE:CGA) stock drifted down 8.53% on Tuesday morning to hit a new 52-week low of $6.74.
    • Kirkland's (NASDAQ:KIRK) stock hit a new 52-week low of $5.64. The stock was down 14.16% on the session.
    • Curis (NASDAQ:CRIS) shares set a new yearly low of $0.70 this morning. The stock was down 1.68% on the session.
    • Elevation Oncology (NASDAQ:ELEV) shares fell to $2.12 on Tuesday, setting a new 52-week low with a shift of down 15.84%.
    • Odyssey Marine Explr (NASDAQ:OMEX) shares set a new 52-week low of $3.60. The stock traded down 5.93%.
    • Ocean Power Technologies (AMEX:OPTT) stock hit $0.82 on Tuesday morning, setting a new 52-week low for a change of down 4.59%.
    • Comera Life Sciences (NASDAQ:CMRA) shares fell to $2.45 on Tuesday, setting a new 52-week low with a shift of up 11.2%.
    • Brenmiller Energy (NASDAQ:BNRG) stock set a new 52-week low of $2.75 on Tuesday, moving down 8.77%.
    • MSP Recovery (NASDAQ:MSPR) stock drifted down 21.84% on Tuesday morning to hit a new 52-week low of $1.09.
    • Assure Hldgs (NASDAQ:IONM) shares reached a new 52-week low of $1.59 on Tuesday morning, moving down 5.88%.
    • Kala Pharmaceuticals (NASDAQ:KALA) stock hit a yearly low of $0.34. The stock was down 1.11% for the day.
    • Inspira Technologies Oxy (NASDAQ:IINN) stock achieved a new 52-week low on Tuesday morning, hitting $1.50 and moving down 1.84%.
    • Genocea Biosciences (NASDAQ:GNCA) shares made a new 52-week low of $0.05 on Tuesday. The stock was down 9.03% for the day.

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $ALXO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALXO
    $BIG
    $BNR
    $CGA

    CompanyDatePrice TargetRatingAnalyst
    PTC Therapeutics Inc.
    $PTCT
    4/10/2026$108.00Outperform
    Raymond James
    ALX Oncology Holdings Inc.
    $ALXO
    3/19/2026$5.00Overweight
    Wells Fargo
    ALX Oncology Holdings Inc.
    $ALXO
    3/6/2026$6.00Buy
    UBS
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    PTC Therapeutics Inc.
    $PTCT
    1/28/2026$119.00Overweight
    Barclays
    Clearwater Analytics Holdings Inc.
    $CWAN
    1/26/2026$24.55Buy → Neutral
    UBS
    Clearwater Analytics Holdings Inc.
    $CWAN
    1/16/2026$24.55Buy → Neutral
    DA Davidson
    Clearwater Analytics Holdings Inc.
    $CWAN
    12/22/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ALXO
    $BIG
    $BNR
    $CGA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Stratmann Philipp bought $2,558 worth of shares (7,750 units at $0.33), increasing direct ownership by 2% to 518,440 units (SEC Form 4)

    4 - Ocean Power Technologies, Inc. (0001378140) (Issuer)

    12/16/25 4:05:27 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    CFO Powers Robert Patrick bought $5,000 worth of shares (14,723 units at $0.34), increasing direct ownership by 6% to 268,132 units (SEC Form 4)

    4 - Ocean Power Technologies, Inc. (0001378140) (Issuer)

    12/15/25 4:05:12 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    $ALXO
    $BIG
    $BNR
    $CGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $202,094 worth of shares (2,850 units at $70.91), decreasing direct ownership by 0.72% to 394,070 units (SEC Form 4) to satisfy withholding tax

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    4/23/26 5:20:06 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Rozanovich Yoav

    3 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Issuer)

    4/23/26 7:45:16 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Krishnan K Ranga

    4 - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Issuer)

    4/22/26 4:47:18 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    $ALXO
    $BIG
    $BNR
    $CGA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ALXO
    $BIG
    $BNR
    $CGA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ALXO
    $BIG
    $BNR
    $CGA
    SEC Filings

    View All

    Raymond James initiated coverage on PTC Therapeutics with a new price target

    Raymond James initiated coverage of PTC Therapeutics with a rating of Outperform and set a new price target of $108.00

    4/10/26 8:34:55 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on ALX Oncology with a new price target

    Wells Fargo initiated coverage of ALX Oncology with a rating of Overweight and set a new price target of $5.00

    3/19/26 8:25:33 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on ALX Oncology with a new price target

    UBS resumed coverage of ALX Oncology with a rating of Buy and set a new price target of $6.00

    3/6/26 8:38:03 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    4/23/26 4:30:39 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Outlook Therapeutics Inc.

    424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)

    4/23/26 7:30:17 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Community Health Systems Inc.

    8-K - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Filer)

    4/22/26 8:20:46 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    $ALXO
    $BIG
    $BNR
    $CGA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearwater Analytics to Announce First Quarter 2026 Financial Results on May 7, 2026

    Clearwater Analytics Holdings, Inc. (NYSE:CWAN), ("CWAN" or the "Company"), the most comprehensive technology platform for investment management, will release financial results for the first quarter ended March 31, 2026 after the U.S. financial markets close on Thursday, May 7, 2026. As a result of the execution of a definitive agreement (the "Merger Agreement") pursuant to which an investor group led by Permira and Warburg Pincus will acquire all of the outstanding shares of the Company's common stock in an all-cash transaction (the "Proposed Transaction"), as announced on December 21, 2025, the Company will not host an earnings conference call or webcast to discuss its first quarter 202

    4/23/26 4:15:00 PM ET
    $CWAN
    Computer Software: Prepackaged Software
    Technology

    Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

    ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics" or the "Company"), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 16,129,033 shares of its common stock at an offering price of $0.31 per share of common stock. Additionally, in a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 16,129,033 shares of common stock at an exercise price

    4/23/26 4:05:00 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Community Health Systems, Inc. Announces Commencement of Tender Offer for Certain Outstanding Senior Secured Notes

    Community Health Systems, Inc. (the "Company") (NYSE:CYH) today announced that its wholly-owned subsidiary, CHS/Community Health Systems, Inc. (the "Issuer") has commenced a tender offer (the "Tender Offer") to purchase for cash up to $600,000,000 aggregate purchase price (exclusive of accrued and unpaid interest) (as such aggregate purchase price may be increased or decreased by the Issuer, the "Aggregate Maximum Purchase Amount") of its outstanding Notes of the two series listed in the table below (collectively, the "Notes"); provided that the Issuer will only accept for purchase (i) its 4.750% Senior Secured Notes due 2031 having an aggregate purchase price of up to $350,000,000 (exclusi

    4/22/26 7:10:00 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    $ALXO
    $BIG
    $BNR
    $CGA
    Leadership Updates

    Live Leadership Updates

    View All

    Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion

    RA'ANANA, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- Inspira Technologies OXY B.H.N. Ltd (NASDAQ:IINN, IINNW)) ("Inspira Technologies" or the "Company") today announced the appointment of Mr. Yoav Rozanovich as Chief Business Officer ("CBO") of Inspira Technologies, reinforcing its commercial execution capabilities following its expansion into quantum computing connectivity and the acquisition of the Additive Manufacturing of Electronics ("AME") business from Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension"). Proven Commercial LeadershipMr. Rozanovich brings international experience across additive manufacturing, advanced electronics, and complex systems integration. From November 2021

    4/14/26 8:01:00 AM ET
    $IINN
    $NNDM
    $SSYS
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology

    ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

    - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (("ALX Oncology, NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026. "Jeff is a highly accomplished leader with deep expertise across clinical development and operations, and a strong track record of both advancing innovative thera

    4/13/26 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

    WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished biotechnology investment banker with an extensive list of achievements over her long tenure at Morgan Stanley, including building and leading the bank's biotechnology franchise.  "I have closely followed Jessica's illustrious career, and I am proud to welcome her to PTC's Board of Directors," said Michael Schmertzler, Chairman of the Board of Directors. "Jessica will play an integral role as the Board continues to work with the management team on charting the company's next stage of growth."Ms. Ch

    3/25/26 8:30:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    $BIG
    $BNR
    $CGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ocean Power Technologies Inc.

    SC 13G/A - Ocean Power Technologies, Inc. (0001378140) (Subject)

    11/27/24 1:43:24 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:50:19 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 7:22:54 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    $BIG
    $BNR
    $CGA
    Financials

    Live finance-specific insights

    View All

    Clearwater Analytics to Announce First Quarter 2026 Financial Results on May 7, 2026

    Clearwater Analytics Holdings, Inc. (NYSE:CWAN), ("CWAN" or the "Company"), the most comprehensive technology platform for investment management, will release financial results for the first quarter ended March 31, 2026 after the U.S. financial markets close on Thursday, May 7, 2026. As a result of the execution of a definitive agreement (the "Merger Agreement") pursuant to which an investor group led by Permira and Warburg Pincus will acquire all of the outstanding shares of the Company's common stock in an all-cash transaction (the "Proposed Transaction"), as announced on December 21, 2025, the Company will not host an earnings conference call or webcast to discuss its first quarter 202

    4/23/26 4:15:00 PM ET
    $CWAN
    Computer Software: Prepackaged Software
    Technology

    PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

    WARREN, N.J., April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, May 7, 2026, at 4:30 p.m. ET. To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to r

    4/22/26 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Community Health Systems, Inc. Announces First Quarter Ended March 31, 2026 Results

    Community Health Systems, Inc. (NYSE:CYH) (the "Company") today announced financial and operating results for the three months ended March 31, 2026. The following highlights the financial and operating results for the three months ended March 31, 2026. Net operating revenues totaled $2.965 billion. Net loss attributable to Community Health Systems, Inc. stockholders was $(58) million, or $(0.43) per share (diluted), compared to $(13) million, or $(0.10) per share (diluted), for the same period in 2025. Excluding the adjusting items as presented in the table in footnote (e) on page 12, net loss attributable to Community Health Systems, Inc. stockholders was $(0.48) per share (diluted

    4/21/26 4:15:00 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care